Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have been assigned a consensus recommendation of “Moderate Buy” from the twelve research firms that are covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $42.60.

Several research analysts recently commented on KYMR shares. HC Wainwright reaffirmed a “buy” rating and issued a $46.00 price objective on shares of Kymera Therapeutics in a report on Monday, June 17th. Oppenheimer reiterated an “outperform” rating and issued a $52.00 price target on shares of Kymera Therapeutics in a research report on Wednesday, July 10th. Finally, B. Riley raised their target price on Kymera Therapeutics from $31.00 to $36.00 and gave the stock a “neutral” rating in a research note on Tuesday, July 9th.

Kymera Therapeutics Stock Performance

Shares of KYMR opened at $39.45 on Thursday. The firm has a market cap of $2.42 billion, a P/E ratio of -15.72 and a beta of 2.22. Kymera Therapeutics has a fifty-two week low of $9.60 and a fifty-two week high of $48.70. The business has a 50-day moving average of $36.39 and a 200 day moving average of $36.81.

Insider Transactions at Kymera Therapeutics

In other news, Director Joanna Horobin sold 8,500 shares of the company’s stock in a transaction dated Friday, June 7th. The shares were sold at an average price of $32.99, for a total transaction of $280,415.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Kymera Therapeutics news, Director Bruce Booth sold 453,960 shares of the company’s stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of $38.21, for a total value of $17,345,811.60. Following the completion of the transaction, the director now directly owns 723,246 shares in the company, valued at approximately $27,635,229.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Joanna Horobin sold 8,500 shares of the business’s stock in a transaction dated Friday, June 7th. The shares were sold at an average price of $32.99, for a total transaction of $280,415.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 502,345 shares of company stock worth $19,279,932. Insiders own 15.82% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD lifted its holdings in shares of Kymera Therapeutics by 18.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,332,012 shares of the company’s stock valued at $254,548,000 after purchasing an additional 996,300 shares during the last quarter. BVF Inc. IL increased its holdings in shares of Kymera Therapeutics by 8.9% during the fourth quarter. BVF Inc. IL now owns 5,161,801 shares of the company’s stock valued at $131,419,000 after acquiring an additional 422,797 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Kymera Therapeutics by 19.2% in the 1st quarter. Vanguard Group Inc. now owns 4,767,050 shares of the company’s stock worth $191,635,000 after purchasing an additional 769,486 shares during the last quarter. Avoro Capital Advisors LLC boosted its stake in Kymera Therapeutics by 3.0% in the 1st quarter. Avoro Capital Advisors LLC now owns 3,888,888 shares of the company’s stock worth $156,333,000 after purchasing an additional 113,888 shares in the last quarter. Finally, Artal Group S.A. increased its stake in Kymera Therapeutics by 19.6% during the 1st quarter. Artal Group S.A. now owns 3,027,135 shares of the company’s stock valued at $121,691,000 after purchasing an additional 496,400 shares in the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.